Zura Bio (NASDAQ:ZURA) Shares Down 6.5% - Here's What Happened

Key Points

• Shares fell 6.5% to $5.665 on Tuesday on lighter trading (278,636 shares, down 58% versus the 669,258 average), giving the company a market cap of about $537.5 million.
• Quarterly earnings missed: Zura reported EPS of ($0.49) versus the consensus ($0.18), a $0.31 shortfall, and analysts expect roughly -0.65 EPS for the year.
• Major insider buying amid mixed analyst views: Ai Biotechnology acquired 2,000,000 shares at $6.25 (a 43.93% increase in its stake), while the sell‑side consensus is a “Moderate Buy” with a $10.75 target.

Shares of Zura Bio Limited (NASDAQ:ZURA - Get Free Report) traded down 6.5% during trading on Tuesday . The company traded as low as $5.73 and last traded at $5.6650. 278,636 shares traded hands during mid-day trading, a decline of 58% from the average session volume of 669,258 shares. The stock had previously closed at $6.06.

Wall Street Analysts Forecast Growth

ZURA has been the topic of a number of recent analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Zura Bio in a report on Friday, January 9th. Oppenheimer reduced their target price on Zura Bio from $16.00 to $15.00 and set an "outperform" rating on the stock in a report on Friday, March 20th. Chardan Capital raised their target price on Zura Bio from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Monday, March 23rd. Finally, Wedbush initiated coverage on Zura Bio in a report on Monday, February 9th. They set an "outperform" rating and a $15.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $10.75.

Zura Bio Trading Down 6.5%

The firm has a market cap of $537.50 million, a P/E ratio of -5.34 and a beta of 0.24. The company has a fifty day moving average price of $6.24 and a two-hundred day moving average price of $4.86.

Zura Bio (NASDAQ:ZURA - Get Free Report) last released its quarterly earnings data on Thursday, March 19th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.31). As a group, sell-side analysts expect that Zura Bio Limited will post -0.65 EPS for the current year.

Insider Buying and Selling at Zura Bio

In other Zura Bio news, major shareholder Ai Biotechnology Llc acquired 2,000,000 shares of the business's stock in a transaction dated Thursday, February 26th. The shares were acquired at an average price of $6.25 per share, for a total transaction of $12,500,000.00. Following the acquisition, the insider directly owned 6,552,725 shares of the company's stock, valued at approximately $40,954,531.25. This trade represents a 43.93% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 14.23% of the stock is owned by company insiders.

Hedge Funds Weigh In On Zura Bio

Several institutional investors have recently modified their holdings of the business. Seven Fleet Capital Management LP bought a new position in shares of Zura Bio during the 4th quarter valued at about $872,000. XTX Topco Ltd bought a new position in shares of Zura Bio during the 4th quarter valued at about $348,000. Suvretta Capital Management LLC lifted its holdings in shares of Zura Bio by 1.7% during the 4th quarter. Suvretta Capital Management LLC now owns 5,567,001 shares of the company's stock valued at $29,171,000 after purchasing an additional 94,110 shares in the last quarter. Quadrature Capital Ltd bought a new position in shares of Zura Bio during the 4th quarter valued at about $192,000. Finally, Millennium Management LLC lifted its holdings in shares of Zura Bio by 75.1% during the 4th quarter. Millennium Management LLC now owns 1,032,680 shares of the company's stock valued at $5,411,000 after purchasing an additional 442,980 shares in the last quarter. Institutional investors own 61.14% of the company's stock.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.